Oncology

Academic Medical Center (AMC)

jasper — 2007-10-17T15:27:17Z

Academic Medical Center (AMC)
Meibergdreef 9
1105 AZ Amsterdam
Website Academic Medical Center
E-mail Amsterdam Medical Center
T +31 (0)20 566 50 56
F +31 (0)20 566 91 68

Employees in Amsterdam: 6,500
Employees in R&D: 1,400
Year of foundation: 1983

Company Profile

AMC is internationally renowned for its expertise in HIV, cardiovascular diseases, metabolic disorders and gastroenterology. At its premises several dedicated research institutes such as the NIN (Netherlands Institute for Neurosciences) and the medical department of the Royal Tropical Institute are housed, as are several biotechnology companies, such as Oncomethylome Sciences and AMC spin-offs AMT and Arthrogen. In order to accommodate more biomedical institutes and companies on the campus, AMC is currently building the Medical Business Park, which will provide 100,000 m² of new space for laboratories and offices, as well as an incubator for start-ups. This concentration of expertise makes AMC much more than an academic hospital, and provides a breeding ground for fruitful scientific collaboration and business.

Science and Technologies or Services

AMC is active in the following research fields:

Cardiovascular Diseases
Gastr-intestinal diseases
Immunity and Infections
Metabolic Disorders
Neurologic and Psychiatric Disorders
Oncology
Public Health and Epidemiology

AMC also offers advanced facilities and highly qualified personnel in the areas of gene and cell therapies, viral vector production, genomics, proteomics, metabolomics, bioinformatics, imaging, and animal models.

Alliances

AMC spin-offs:

AIMM Therapeutics
AMCAS
Amsterdam Molecular Therapeutics (AMT)
Arthrogen
Hep-Art Medical Devices
IATEC
Macrozyme
MicroVision Medical
Primagen
Valletta Health

Keywords

Academic hospital
Medical research
License opportunities
Spin-off companies

Agendia

Sandra Migchielsen — 2007-10-17T15:27:17Z

Agendia B.V.
Science Park 406
1098 XH Amsterdam
Website Agendia B.V.
E-mail Agendia B.V.
Promotion video Agendia
T +31 (0)20 462 15 00
F +31 (0)20 462 15 05

Employees in Amsterdam: 65
Employees in R&D: 9
Year of foundation: 2003

Company Profile

Agendia is committed to improving the quality of life of people suffering from cancer. The company is a world leader in gene expression analysis-based diagnostics and has developed a series of validated, state of the art tests using tumor gene expression profiling. The tests help oncologists make the right decision regarding the treatment of the individual cancer patient. Agendia was the first company to commercialise a prognostic test, MammaPrint, which predicts the risk of breast cancer recurrence. MammaPrint was cleared by the US Food and Drugs administration in February 2007.
Agendia was founded in 2003 by Netherlands Cancer Institute (NKI) researchers Laura van 't Veer, René Bernards and Bernhard Sixt and is located in Amsterdam in the Netherlands. Agendia is now in the market with three products: MammaPrint, CupPrint and DiscoverPrint.

Science and Technologies or Services

Agendia has developed high-quality diagnostic methods using microarray gene expression profiling to determine tumor specific properties. Our in vitro diagnostic laboratory services offered to physicians and pharmaceutical companies improve the accuracy of metastasis risk prediction, disease origin, targeted drug development or pre-selection of patients eligible for clinical trials.

Alliances

Netherlands Cancer Institute

Keywords

Gene expression analysis
Genomic profiling
Microarray
Cancer
Diagnostic
MammaPrint
CupPrint
DiscoverPrint

AIMM Therapeutics B.V.

jasper — 2007-10-17T15:27:17Z

AIMM Therapeutics B.V.
Meibergdreef 45
1105 BA Amsterdam
Website AIMM Therapeutics B.V.
E-mail AIMM Terapeutics B.V.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 58

Employees in Amsterdam: 5
Employees in R&D: 5
Year of foundation: 2005

Company Profile

AIMM’s portfolio is based on proprietary platform technologies for directed, fast and efficient development of fully human monoclonal antibodies. Many innovative products for a wide range of viral and bacterial diseases as well as for cancer, are being developed.

Science and Technologies or Services

The goal is to isolate antibody-producing B cells from humans that have resolved a pathogenic challenge with high or exceptional efficiency. This would allow for the direct isolation of monoclonal antibodies with proven effectiveness in a clinical setting. Such proprietary B cell immortalization technologies for the selective isolation of human B cells shall lead to antibodies with desirable specificities.

Alliances

AMC-Amsterdam;
UMCU-Utrecht;
NVI-Bilthoven.

Keywords

Human antibodies;
Vaccines.

Axon Lawyers

Josje Spinhoven — 2011-06-16T09:20:00Z

Piet Heinkade 183
1019 HC Amsterdam
Website
E-mail
T +31 (0)88 650 6500
F +31 (0)88 650 6555

Employees: 3
Employees in R&D: 0
Year of foundation: 2011

Company Profile

We focus entirely on the life sciences, together we have over 20 years of experience in the life science sector both as attorney at law and as in-house counsel.

Keywords

law
legal services
coaching of high tech and life sciences start-up and spin-out companies

Clinical Reach Drug Development b.v.

Anne de Graaf — 2010-02-18T15:00:00Z

Clinical Reach Drug Development b.v.
Zoeterwoudseweg 74
2321 GP Leiden
Website Clinical Reach
E-mail Clinical Reach
T +31 (0)71 531 18 52

Employees in Amsterdam: 1
Employees in R&D: 1
Year of foundation: 2009

Company Profile

Clinical Reach is an independent company that aims to be a partner in your development team, from the strategic level down to the level of hands-on support in the execution of individual studies.

Company Profile

We join you in your goal to develop a product that meets regulatory expectations and that will be commercially successful. Pending your needs, we support you in your efforts to:

Define the target product profile.
Define the development plan that brings you to that target.
Seek key opinion leader and regulatory authority challenge of the target product profile and development plan.
Design the individual studies in your development plan.
Identify the appropriate contract research organization to execute your studies, and work with this external partner on a day-to-day basis until the study has been reported.
Present your plans and data to external parties, including investors, potential licensing partners and regulatory agencies.

Alliances

We are informally associated with various expert companies and individual experts providing services complementary to those of Clinical Reach, including:

Regulatory services.
Pharmaceutical development and clinical trial material production, packaging and labeling.
Clinical study execution and management services.
Recording and reporting of electronic patient-reported outcome (ePRO) data.
Bioanalytical services, including biomarker assays and immunogenicity assessments.
Pharmacokinetic and –dynamic data analysis.
Modeling and simulation from clinical trial design to kinetic and dynamic data.
Data management and statistics.
Medical writing.

Keywords

Target product profile
drug development
regulatory challenge
key opinion leader challenge
study design and execution

DC Prime B.V.

jasper — 2007-10-17T15:27:17Z

DC Prime B.V.
De Boelelaan 1085
1081 HV Amsterdam
Website DC Prime B.V.
E-mail DC Prime B.V.
T +31 (0)6 5517 21 58
F +31 (0)20 598 99 04

Employees in Amsterdam: 9
Employees in R&D: 9
Year of foundation: 2005

Company Profile

DCPrime BV is a spin-off company of the VU university medical center (VUmc) in Amsterdam, and focused on creating new therapeutic vaccines for the treatment of cancer and autoimmunity. The company develops products based on unique technologies developed at the VUmc. These include a panel of sustainable dendritic cell (DC) lines, and novel DC targeting technologies. DCPrime BV is gearing up to provide clinical proof-of-concept on DC lines for one indication before the end of 2009.

Science and Technologies or Services

In one arm of its technology base, DCPrime develops sustainable DC lines that can be clinically applied as off-the-shelf DC vaccines. These can be loaded with the desired tumor antigens, but also with viral antigens or antigens for which tolerance is desirable. Also other genes of interest can be introduced into these DC lines without harming their antigen presentation potential, to introduce desirable modulations.
The first DC line, DCOne, is currently being prepared for entering clinical testing, and with several external partners. Scale-up procedures are being developed, and QA/QC compliant dossiers are being built on product specifications, production parameters, harvesting and storage conditions, quality assays, and reproducibility of all processes.
In the second arm of its technology base, DCPrime is performing pre-clinical validation of innovative DC targeting tools that can be directly applied to skin. The technological basis for these products will be prepared for strategic collaborations with co-development partners.

Alliances

DCPrime BV works together with the VU medical center, and with many life sciences companies and CRO’s in Europe.

Keywords

Cancer
Immunotherapy
Autoimmunity
Dendritic cells

DC4U B.V.

Maarten — 2007-10-17T15:27:17Z

DC4U B.V.
Van der Boechorststraat 7
1081 BT Amsterdam
E-mail DC4U B.V.
T +31 (0)20 444 80 84
F +31 (0)20 444 80 81

Year of foundation: 2006

Company Profile

DC4U B.V. aims to develop therapeutic and diagnostic tools for cancer. The company owns the exclusive worldwide license for all existing and all future IP in the field of glycoproteins and glycosylation processes involved in immune signalling, for use in the development of vaccines or therapeutics or diagnostics in the areas of infectious diseases, immunological disorders and cancer. DC4U B.V. has a strong team with scientific, legal, financial, commercial, IP and licensing expertise.

Science and Technologies or Services

Recently, glycomics research has yielded potential leads that may provide innovative solutions for the treatment of cancer. Glycomics is a new biomedical discipline that investigates how sugar modification of macromolecules (glycosylation) affects their biological and pathological function. Recent exciting discoveries in this field, in which Prof. Dr. Y. van Kooyk has a world-leading role, are further explored. DC4U B.V. strongly believes that liposomes containing highly specific APC-targeting signals using glycans provide the answer in the search for a new vaccine to cure colon cancer. The fact that certain glycans can target two different APC subsets allows us for the first time to design a vaccine that targets both subsets that have strong immune-modulating capacity.

Alliances

Drug Discovery Factory B.V.
VU Medical Center Amsterdam
Octoplus Technologies B.V.
Utrecht University
Technical University Munchen

Keywords

Cancer
Therapeutics
Vaccines
Immunotherapy
Autoimmunity
Dendritic Cells
Drug Discovery

Drug Discovery Factory BV

Maarten — 2007-03-19T09:00:00Z

Drug Discovery Factory BV
Albrechtlaan 14a
1404 AK Bussum
Website Drug Discovery Factory B.V.
E-mail Drug Discovery Factory B.V.
T +31 (0)35 695 40 50

Employees in Amsterdam: 14
Employees in R&D: 10
Year of foundation: 2003

Company profile

Currently the DDF group consists of 12 companies in the life sciences Using a hands-on approach and dedication to meet customer demands we aim to create value for our clients and other stakeholders. Peter Schoevers and Henk Viëtor, the founders of DDF, have established themselves as two of the leading Life Sciences entrepreneurs behind successful companies such as Recharge, DCPrime, Skyline Diagnostics, Dynomics and Julius Clinical Research.

Science and Technologies or Services

Selecting
DDF selects the most attractive research projects at leading University Medical Center and other research institutions.

Financing
DDF provides and/or organizes funding and grants.

Managing
DDF monitors the projects, files patents, finds partners, provides (project) management.

Commercialising
DDF markets and sells projects, products and services.

Consulting
The team of 14 employees of DDF undertakes management activities, consultancy activities, IP management and financial administration activities.

Alliances

We have a dedicated network of partners to realize research and development projects and work closely with academic hospitals, regulatory authorities and local and national governments.

Keywords

Drug development;
University;
Intellectual property;
Consultancy;
Entrepreneurship;
Commercialisation.

Dynomics B.V.

rgeerts — 2009-12-07T13:00:00Z

Dynomics B.V.
P.O. Box 82
1400 AB Bussum
Website Dynomics B.V.
E-mail Dynomics B.V.
T +31 (0)10 704 40 94
F +31 (0)10 704 47 31

Employees in Amsterdam:
Employees in R&D:
Year of foundation: 2001

Company Profile

Dynomics aims to be the worldwide leader in the development of tests that provide diagnostic information on the classification of leukemia and lymphoma and information on the prognosis and staging of the disease.
The developed tests present the clinician with a meaningful improvement over current methods for diagnosing leukemia and lymphoma.

Science and Technologies or Services

Currently available diagnostic tests for leukemia diagnosis are relatively expensive and take a long processing times (at least 2 to 3 days). It is important for a diagnostic test to provide rapid results. Also the precise classification of leukemia has major implications for prognosis, treatment choice and dosage. For example, the Dynomics' multiplex single tube assay for detection and identification of fusion proteins derived from chromosome aberrations provides a result in a few hours, whereas the traditional tests for detection of chromosome with fusion genes can take up to several days. Once the treatment has been chosen, the physician can monitor the effectiveness of the leukemia treatment during follow-up with the Dynomics' single fusion tube protein detection kit.
Dynomics is working on the development of the first kit for disease (sub-) classification and progression measurement and on kits containing antibodies against molecules in lymphoid development for (sub) classification of leukemias and lymphoma and possibly for evaluation of B-cell and T-cell subsets in auto-immune diseases and allergies.

Alliances

Dynomics BV works together with the Erasmus Medical Center, and with many life sciences companies and large pharma.

Keywords

Leukemia
Lymphomas
Cancer
Fusion Proteins
Drug Discovery
Diagnostics.

Exscensus Management Consulting

Josje Spinhoven — 2011-06-16T09:16:47Z

Schutteheiweg 37
6343AG Klimmen
Website
e-mail
T +31 (0)6 5460 7087

Employees: 1
Year of foundation: 2008

Company Profile

Science and Technologies or Services

Alliances

Keywords

Genmab B.V.

jasper — 2007-10-17T15:27:17Z

Genmab B.V.
Yalelaan 60
3508 AD Utrecht
Website Genmab B.V.
T +31 (0)30 212 31 23
F +31 (0)30 212 31 10

Employees in Amsterdam: 130
Employees in R&D: 130
Year of foundation: 2001

Company Profile

Genmab is headquartered in Copenhagen (Denmark) and has operations in Utrecht (The Netherlands), Princeton (US), Brooklin Park (US) and Stevenage (UK). From its Research & Discovery facilities in Utrecht, The Netherlands, the preclinical activities take place. After characterization and optimisation of lead candidates, the human antibodies are clinically evaluated by Genmab A/S, the corporate headquarter in Copenhagen, Denmark. This location also accommodates the regulatory and medical departments. From Genmab Inc. in Princeton, USA the US clinical activities are coordinated. From Genmab Ltd. in Hitchin, UK the UK clinical activities are coordinated.

Science and Technologies or Services

Genmab uses a combination of innovative technology platforms in multidisciplinary teams of biologists, biochemists and MD's. Antibodies, one of the body’s most important natural defenses, are proteins that seek out, recognize and bind to disease targets. A specific antibody directs the immune system to a particular target like a key fitting into a lock. It is this specificity that makes antibodies potentially useful in various therapeutic applications. Our skilled pre-clinical team, located in Utrecht, ensures that the best possible antibody candidate is selected to become a potential product. A panel of antibodies is generated and these antibodies are put through a rigorous series of laboratory functional assays designed to identify characteristics of the best therapeutic product.

Alliances

At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with GlaxoSmithKline and Roche.

Keywords

Genmab;
Biotech;
Human antibodies;
Monoclonal antibodies;
Drug discovery;
Drug development;
Pre-clinical;
Oncology;
Inflammatory diseases;
Infectious diseases.

Genzyme Nederland

jasper — 2007-10-17T15:27:17Z

Genzyme Nederland
Gooimeer 10
1411 DD Naarden
Website Genzyme Nederland
E-mail Genzyme Nederland
Promotion video Genzyme Nederland
T +31 (0)35 699 86 00
F +31 (0)35 699 86 21

Employees in Amsterdam: 415
Employees in R&D: 150
Year of foundation: 1991

Company Profile

Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in Boston in 1981, Genzyme has grown from a small start-up to a diversified enterprise with annual revenues exceeding $3 billion and more than 9,500 employees in locations spanning the globe. With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. Genzyme’s European office was founded in 1991 and now harbors over 400 people. These people are involved in European clinical research, regulatory affairs, medical info, pharmacovigilance, datamanagement, marketing, sales, finance, customer services, IT and HR.

Science and Technologies or Services

Genzyme’s research and development efforts are focused on the areas of medicine where it markets commercial products. The company also conducts research in cardiovascular disease and other areas of unmet medical need. In 2006, the company invested approximately $565 million in this work, or about 18 percent of its revenues. Genzyme identifies unmet medical needs and its large team of scientists and researchers uses a broad range of scientific approaches and technologies to meet those needs. The company is a leader in novel areas such as cell and gene therapies and biomaterials. Genzyme also partners with other companies to develop new products and supports research conducted by top academic and independent medical science centers.

Alliances

Genzyme has many different alliances with companies and research groups around the world. In the Netherlands Genzyme is collaborating with Macrozyme BV in the area of diabetes and scientific and clinical projects are ongoing with researchers in several academic centers, including the AMC.

Keywords

Orphan diseases
Renal disease
Oncology
Transplant
Orthopedics
Familial Hypercholesterolemia

Greenberg Traurig LLP

Josje Spinhoven — 2011-04-06T10:25:00Z

Greenberg Traurig LLP
Strawinkskylaan 3127
1077 ZX Amsterdam
Website
E-mail
T +31 20 301 7436
F +31 20 301 7350

Employees: 100
Employees in R&D: 60
Year of foundation: 2003

Company Profile

Greenberg Traurig is a law firm of 1800 lawyers in more than 30 locations focused on helping businesses navigate change in every way. Through its offices in the US, Europe and Asia it has a global reach yet local footprint.

Science and Technologies or Services

GT provides world-class and worldwide industry-oriented life sciences legal services in all areas of law, including IP, licensing, M&A, regulatory compliance, litigation, etc.

Alliances

Through its alliance partners GT can provide legal services in markets where it is not established itself, enabling GT to provide legal services in every country in the world.

Keywords

Legal
Regulatory
M&A
Contracts
Litigation

Holland Health

rgeerts — 2009-03-31T12:50:00Z

Holland Health
Comeniusstraat 10
1817 MS Alkmaar
Website Holland Health
E-mail Holland Health
T +31 (0)72 519 57 74
F +31 (0)72 519 58 77

Employees in Amsterdam: 1
Employees in R&D: 1
Year of foundation: 2008

Company profile

Medical cluster foundation which stimulates health care

Science and Technologies or Services

Supports science en technology innovation by knowledge and venture capital

Alliances

Ontwikkelingsbedrijf Noord-Holland Noord;
Medical Center Alkmaar;
Tromp Medical;
Kamer van Koophandel;
Boehringer Ingelheim;
H&S Adviesgroep;
NRG Petten.

Keywords

Medical innovation

Horlings Accountants and Tax advisors

Josje Spinhoven — 2011-07-04T13:45:00Z

Jozef Israëlskade 46
1072 SB Amsterdam
Website
E-mail
T +31(0)20 570 02 00
F +31(0)20 676 44 78

Employees: 160
Employees in R&D: 0
Year of foundation: 1973

Company Profile

HORLINGS Accountants and Tax Consultants is a professional services firm employing over 160 professionals in Amsterdam, Heemstede and Hoofddorp. Our Amsterdam team of consultants specializes in international (tax) advice for corporates and (their) employees. We have a firm and well-known experience in providing full service to our clients and are able to respond swift and accurate to all your questions and queries.
At Horlings we continuously challenge each other to improve our performance even further. We closely follow every new development in our chosen area of expertise as well as that of our clients. Because we are driven by the same ambition as our clients: to dare to be the best!
Horlings not only has many life science companies as a tax and/or accountancy client, we also have a proven track record in arranging the new Dutch Innovation Box regime for many of these clients. Because Horlings knows the business like no other, we are able to cooperate swift and (cost-)efficient.

Science and Technologies or Services

Review or audit of (consolidated) accounts, IFRS and US Gaap knowledge, Valuations, VAT advice and VAT compliance (Dutch and EU), Corporate income tax advice and return, M&A, transfer pricing, rulings, Tax litigation (all courts), Payroll, Transaction services, IT Audit.

Alliances

Together with Koenen en Co and KroesWevers we form the alliance Nexia Nederland, one of the 10 largest accountants and consulting firms of the Netherlands with approximately 700 professionals. The member firms are independent and combine the benefits of a larger as well as a smaller organisation.
Nexia Nederland is member of Nexia International, a network of independent accountants and consulting firms with 620 offices in 97 countries. Nexia International is one of the worlds’ largest networks of professional services.

Keywords

Tax, Account, Payroll, VAT, Audit, Expat, Amsterdam, Finance, Service